Thus, the aim of this study was to evaluate the potential role of serum syndecan-4 as a novel biomarker for disease severity in CD, by concentrations with myocardial fibrosis and left ventricular ejection fraction (LVEF). The gene discussed is SDC4; the disease is Myocardial fibrosis.